MedTrace Logo

Reaching for Evidence-baSed Chemotherapy Use in Endocrine Sensitive Breast Cancer

NCT03503799 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 1191

Last updated 2026-04-13

No results posted yet for this study

Summary

Systematic assessment of survival data of patients who have been tested with EndoPredict®; prospective proof that patients with low risk classification by EndoPredict® (EPclin) can safely forgo chemotherapy and be treated with endocrine therapy alone.

Conditions

  • Estrogen Receptor Positive Tumor
  • Primary Invasive Breast Cancer
  • Human Epidermal Growth Factor Receptor 2 Negative Tumor

Interventions

OTHER

Observation

Visit 1 Informed consent Medical history Demographics Result of EndoPredict® Test Status of menopause Disease status Tumor board decision Planned anti-tumor-therapy Visit 2, 1 year after inclusion This visit will be documented at the study site Status of menopause Disease status Anti-tumor therapy Survival Following visits For these visits, patients will be asked directly through the Center for Clinical Trials of the Philipps-University Marburg (KKS Marburg) via phone. Status of Menopause Disease status Anti-tumor therapy Survival Treatment after end of the study The patient will be treated during and after end of study by physician's choice.

Sponsors & Collaborators

  • Coordinating Center for Clinical Trials (KKS; Philipps-University of Marburg, Germany)

    collaborator UNKNOWN

  • North Eastern German Society of Gynaecological Oncology

    lead OTHER

Principal Investigators

  • Marion Kiechle, Prof. Dr. · TU München (TUM) Lehrstuhl für Gynäkologie und Geburtshilfe

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-17
Primary Completion
2032-10-01
Completion
2032-10-01

Countries

  • Germany
  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03503799 on ClinicalTrials.gov